Prevalence of adverse drug reaction in Indonesia: A systematic review

Q2 Pharmacology, Toxicology and Pharmaceutics

journal of applied pharmaceutical science Pub Date : 2023-01-01 DOI:10.7324/japs.2023.91550

Laksmi Maharani, A. Yugatama

{"title":"Prevalence of adverse drug reaction in Indonesia: A systematic review","authors":"Laksmi Maharani, A. Yugatama","doi":"10.7324/japs.2023.91550","DOIUrl":null,"url":null,"abstract":"The prevalence of adverse drug reactions (ADRs) varies among countries. The aim of this systematic review was to provide reliable information regarding the prevalence of ADRs in Indonesia. A literature search of the PubMed database and Google Scholar between 2011 and 2021 was performed using the main keywords “ADRs” and “Indonesia,” with additional keywords based on the database used. We followed the 2020 PRISMA statement guidelines to prepare the review. Critical appraisal and assessment of the risk of bias were performed using the CONSORT, STROBE, CARE, and MINORS guidelines based on the article’s type. From 168 articles recorded in the databases, we included 36 articles after the identification, screening, and eligibility assessment processes. The prevalence of ADR in Indonesia ranged from 0.9% to 99% based on drug use, duration, and doses of therapy. Insulin, cardiovascular agents, and anti-inflammatories were the drugs with the highest occurrence of ADRs (with the maximum percentage in previous research over 60%). The prevalence of ADR in Indonesia is varied and related to the method used in the reporting studies. There is a need for an annual national report on ADR in Indonesia with a similar technique of survey and calculation to produce accurate data on ADR prevalence.","PeriodicalId":15126,"journal":{"name":"journal of applied pharmaceutical science","volume":"80 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"journal of applied pharmaceutical science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7324/japs.2023.91550","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

The prevalence of adverse drug reactions (ADRs) varies among countries. The aim of this systematic review was to provide reliable information regarding the prevalence of ADRs in Indonesia. A literature search of the PubMed database and Google Scholar between 2011 and 2021 was performed using the main keywords “ADRs” and “Indonesia,” with additional keywords based on the database used. We followed the 2020 PRISMA statement guidelines to prepare the review. Critical appraisal and assessment of the risk of bias were performed using the CONSORT, STROBE, CARE, and MINORS guidelines based on the article’s type. From 168 articles recorded in the databases, we included 36 articles after the identification, screening, and eligibility assessment processes. The prevalence of ADR in Indonesia ranged from 0.9% to 99% based on drug use, duration, and doses of therapy. Insulin, cardiovascular agents, and anti-inflammatories were the drugs with the highest occurrence of ADRs (with the maximum percentage in previous research over 60%). The prevalence of ADR in Indonesia is varied and related to the method used in the reporting studies. There is a need for an annual national report on ADR in Indonesia with a similar technique of survey and calculation to produce accurate data on ADR prevalence.

查看原文本刊更多论文

印度尼西亚药物不良反应的发生率:一项系统综述

药物不良反应(adr)的发生率因国家而异。本系统综述的目的是提供有关印度尼西亚不良反应发生率的可靠信息。使用主要关键词“adr”和“Indonesia”对PubMed数据库和谷歌Scholar在2011年至2021年间进行了文献检索，并根据所使用的数据库添加了附加关键词。我们遵循2020年PRISMA声明指南来准备审查。根据文章的类型，采用CONSORT、STROBE、CARE和未成年指南对偏倚风险进行了严格的评估和评估。从数据库中记录的168篇文章中，经过鉴定、筛选和资格评估过程，我们纳入了36篇文章。根据药物使用、持续时间和治疗剂量，印度尼西亚的不良反应发生率为0.9%至99%。胰岛素、心血管药物和抗炎药是adr发生率最高的药物(既往研究中最高百分比超过60%)。印度尼西亚的不良反应发生率各不相同，与报告研究中使用的方法有关。印度尼西亚需要一份关于不良反应的年度国家报告，采用类似的调查和计算技术，以产生关于不良反应发生率的准确数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

journal of applied pharmaceutical science Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

2.20

自引率

0.00%

发文量

224

期刊介绍： Journal of Applied Pharmaceutical Science (JAPS) is a monthly, international, open access, journal dedicated to various disciplines of pharmaceutical and allied sciences. JAPS publishes manuscripts (Original research and review articles Mini-reviews, Short communication) on original work, either experimental or theoretical in the following areas; Pharmaceutics & Biopharmaceutics Novel & Targeted Drug Delivery Nanotechnology & Nanomedicine Pharmaceutical Chemistry Pharmacognosy & Ethnobotany Phytochemistry Pharmacology & Toxicology Pharmaceutical Biotechnology & Microbiology Pharmacy practice & Hospital Pharmacy Pharmacogenomics Pharmacovigilance Natural Product Research Drug Regulatory Affairs Case Study & Full clinical trials Biomaterials & Bioactive polymers Analytical Chemistry Physical Pharmacy.